Creatv Bio's Innovative Blood Test for Colorectal Cancer Trials
Revolutionary LifeTracDx® Blood Test in Colorectal Cancer Trials
Creatv Bio, a division of Creatv MicroTech, Inc., is taking significant strides in the realm of cancer diagnostics. The introduction of their LifeTracDx® blood test in collaboration with CytoDyn Therapeutics Corporation marks a promising development in assessing patient responses to innovative treatments. The synergy between these two innovative companies aims to enhance the understanding of therapeutic efficacy in individuals battling colorectal cancer, specifically through the evaluation of the drug leronlimab.
Understanding the LifeTracDx® Blood Test
The LifeTracDx® test is garnering attention for its ability to deliver crucial insights without the need for invasive tissue sampling. By analyzing circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells through a simple blood draw, this test provides a non-invasive solution to track cancer's progression and response to therapy. These biomarkers are instrumental in yielding critical prognostic insights.
Application in Clinical Trials
Currently, CytoDyn has embarked on a Phase II study, exploring the effectiveness of leronlimab in patients with relapsed or refractory micro-satellite stable colorectal cancer. The ultimate goal is to determine how well this targeted therapy interacts with molecular markers, including CCR5, which is crucial for understanding treatment outcomes. LifeTracDx® plays a pivotal role by allowing researchers to monitor patient responses closely without the procedural burdens of traditional biopsy techniques.
Significant Benefits of LifeTracDx®
One of the standout features of the LifeTracDx® test is its capacity to provide timely prognostic data—potentially within just 30 days of treatment initiation. This rapid feedback loop empowers healthcare providers to make quicker adjustments to patient care plans, which can significantly improve treatment conformity and outcomes.
Tracking Genetic Expression Over Time
The ability of LifeTracDx® to evaluate genetic expressions such as CCR5 and PD-L1 within a patient’s system adds another layer of advantage. The dynamic nature of these markers, which can evolve as the disease progresses or with response to treatment, underscores the need for this form of testing. By regularly assessing these levels, CytoDyn can refine its therapeutic approaches, increasing the chances of successful treatment outcomes for patients.
Elevating Cancer Diagnostics with Creatv Bio
With a foundation rooted in innovation, Creatv Bio is setting new standards in cancer diagnostics. Their commitment to providing comprehensive testing services extends beyond patient care, benefitting pharmaceutical companies as well. The scientists at Creatv are pioneers in the research of CAMLs in cancer patients, ensuring that they remain at the forefront of the ever-evolving field of blood-based cancer diagnostics.
Multifaceted Applications of LifeTracDx®
The LifeTracDx® blood test is not limited to measuring treatment responses. It has various applications, including detecting minimal residual disease, facilitating early detection of cancer recurrence, and enhancing cancer screening methods. The adoption of this innovative test can significantly streamline the complexities associated with cancer diagnosis and management.
About Creatv Bio and Contact Information
Creatv Bio is established as a trusted partner in cancer diagnostics, dedicated to assisting patients and pharmaceutical firms in navigating the complexities of drug development. Their laboratory in New Jersey serves as a hub for groundbreaking research and development in cancer diagnostic protocols. If you seek more information regarding Creatv Bio's innovative solutions, please reach out to:
Daniel Adams - Chief Scientific Officer
Ron Baker - Chief Business Officer
Phone: 732-783-7132 (office)
Mobile: 301-785-5185
Frequently Asked Questions
What is the LifeTracDx® blood test?
The LifeTracDx® test is a blood test that analyzes circulating tumor cells and macrophage-like cells to provide insights into cancer treatment responses.
How does LifeTracDx® benefit colorectal cancer treatments?
It allows for non-invasive monitoring of tumor markers, helping to predict patient responses to therapies quickly and efficiently.
What is the Phase II study mentioned in the article?
It refers to CytoDyn's clinical trial investigating the efficacy of leronlimab in patients with specific types of colorectal cancer.
What markers does the LifeTracDx® test evaluate?
The test evaluates important genetic markers like CCR5 and PD-L1, which are critical for understanding treatment effectiveness.
How can one contact Creatv Bio for more information?
Interested parties can reach out to Daniel Adams at 732-783-7132 or Ron Baker at 301-785-5185 for inquiries about the company and its services.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
